利用大自然的药房:研究天然化合物作为性结肠炎的新疗法
You Huang1,2, Qiuhong Wu1, Sha Li1
1School of Pharmacy/School of Modern Chinese Medicine Industry, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Frontiers in pharmacology
|August 29, 2024
概括
本综述确定了279种可以通过调节肠道微生物群,肠道屏障和免疫反应来治疗性结肠炎 (UC) 的天然化合物. 类化合物,类化合物和黄类化合物显示出开发新的UC疗法的巨大潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其全球发病率正在增加.
- 迫切需要新的治疗策略来治疗UC.
- 天然化合物是开发新的UC药物的有前途来源,但它们的机制尚未得到系统的总结.
研究的目的:
- 系统地审查和总结用于治疗性结肠炎 (UC) 的天然化合物及其作用机制.
- 为寻求新型UC治疗方法的研究人员和临床医生提供全面的资源.
主要方法:
- 在科学网,PubMed,中国国家知识基础设施和万方数据库中进行文献搜索.
- 数据收集的时间从数据库创建到2023年7月.
- 提取和分析了有关自然化合物及其UC治疗机制的信息.
主要成果:
- 279种天然化合物被确定为有效治疗UC.
- 确定了四种主要机制:调节肠道微生物群和代谢物,保护肠道粘膜屏障,调节肠道粘膜免疫反应和其他机制 (例如,自调节,铁灭抑制).
- 类化合物,类化合物和黄类化合物显示出最大的治疗潜力,其中54种化合物调节了所有三个主要机制 (I,II和III).
结论:
- 本综述提供了自然化合物及其UC治疗机制的全面概述.
- 这些发现凸显了天然化合物,特别是类,类和黄类对UC的显著治疗潜力.
- 利用这些天然化合物可以推进疾病修饰疗法,改善UC患者的生活质量.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
375
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
375
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120


